HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.

Abstract
We have shown previously that cathepsin K, a recently identified member of the papain superfamily of cysteine proteases, is expressed selectively in osteoclasts and is the predominant cysteine protease in these cells. Based upon its abundant cell type-selective expression, potent endoprotease activity at low pH and cellular localization at the bone interface, cathepsin K has been proposed to play a specialized role in osteoclast-mediated bone resorption. In this study, we evaluated a series of peptide aldehydes and demonstrated that they are potent cathepsin K inhibitors. These compounds inhibited osteoclast-mediated bone resorption in fetal rat long bone (FRLB) organ cultures in vitro in a concentration-dependent manner. Selected compounds were also shown to inhibit bone resorption in a human osteoclast-mediated assay in vitro. Chz-Leu-Leu-Leu-H (in vitro enzyme inhibition Ki,app = 1.4 nM) inhibited parathyroid hormone (PTH)-stimulated resorption in the FRLB assay with an IC-50 of 20 nM and inhibited resorption by isolated human osteoclasts cultured on bovine cortical bone slices with an IC-50 of 100 nM. In the adjuvant-arthritic (AA) rat model, in situ hybridization studies demonstrated high levels of cathepsin K expression in osteoclasts at sites of extensive bone loss in the distal tibia. Cbz-Leu-Leu-Leu-H (30 mg/kg, intraperitoneally) significantly reduced this bone loss, as well as the associated hind paw edema. In the thyroparathyriodectomized rat model, Cbz-Leu-Leu-Leu-H inhibited the increase in blood ionized calcium induced by a 6 h infusion of PTH. These data indicate that inhibitors of cathepsin K are effective at reducing osteoclast-mediated bone resorption and may have therapeutic potential in diseases of excessive bone resorption such as rheumatoid arthritis or osteoporosis.
AuthorsB J Votta, M A Levy, A Badger, J Bradbeer, R A Dodds, I E James, S Thompson, M J Bossard, T Carr, J R Connor, T A Tomaszek, L Szewczuk, F H Drake, D F Veber, M Gowen
JournalJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (J Bone Miner Res) Vol. 12 Issue 9 Pg. 1396-406 (Sep 1997) ISSN: 0884-0431 [Print] United States
PMID9286755 (Publication Type: Journal Article)
Chemical References
  • Aldehydes
  • Enzyme Inhibitors
  • Oligopeptides
  • Parathyroid Hormone
  • RNA, Messenger
  • Recombinant Proteins
  • Cathepsins
  • CTSK protein, human
  • Cathepsin K
  • Ctsk protein, rat
  • Calcium
Topics
  • Aldehydes (pharmacology)
  • Animals
  • Arthritis, Experimental (metabolism)
  • Bone Resorption
  • Calcium (blood)
  • Cathepsin K
  • Cathepsins (antagonists & inhibitors, genetics)
  • Cattle
  • Enzyme Inhibitors (pharmacology)
  • Female
  • Humans
  • Oligopeptides (pharmacology)
  • Parathyroid Hormone (pharmacology)
  • Parathyroidectomy
  • Pregnancy
  • RNA, Messenger (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins (antagonists & inhibitors)
  • Thyroidectomy
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: